Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial

The Lancet Oncology

Volumn 14, Issue 7, 2013, Pages 627-637

  Crosby, Thomas ^a   Hurt, Christopher N ^b   Falk, Stephen ^c   Gollins, Simon ^d   Mukherjee, Somnath ^e   Staffurth, John ^b   Ray, Ruby ^b   Bashir, Nadim ^b   Bridgewater, John A ^f   Geh, J Ian ^g   Cunningham, David ^h   Blazeby, Jane ⁱ   Roy, Rajarshi ^j   Maughan, Tim ^e   Griffiths, Gareth ^b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^d GLAN CLWYD HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

^j DIANA PRINCESS OF WALES HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN;

ACNE; ADULT; AGED; ANOREXIA; ARTICLE; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EMBOLISM; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOCYTE COUNT; LUNG DISEASE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THROMBOCYTE COUNT; THROMBOSIS; THROMBUS; TREATMENT FAILURE; UNDIFFERENTIATED CARCINOMA; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84878365339     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70136-0     Document Type: Article

References (41)

1. Oesophageal cancer: statistical information on gullet cancer Cancer Research UK, (accessed Feb 28, 2013). http://publications.cancerresearchuk.org/cancerstats/statsoesophapgeal.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727-1733. Medical Research Council Oesophageal Cancer Working Group.
4. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29:1715-1721.
5. Blazeby J, Farndon J, Donovan J, Alderson D A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 2000, 88:1781-1787.
6. Cooper JS, Guo MD, Herskovic A, et al. Chemotherapy of locally advanced esophageal cancer: long term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999, 281:1623-1627.
7. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
8. Crosby TD, Brewster AE, Borley A, et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 2004, 90:70-75.
9. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174.
10. Tsutsumi K, Yasuda M, Nishioka T X-ray irradiation altered chemosensitivity of a p53-null non-small cell lung cancer cell line. Cell Struct Funct 2006, 31:47-52.
11. Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982, 8:1923-1933.
12. Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T Definitive chemoradiation for oesophageal cancer-a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol) 2011, 23:182-188.
13. Wang KL, Wu TT, Choi IS, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007, 109:658-667.
14. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastic colorectal cancer. N Engl J Med 2004, 351:337-345.
15. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
16. Baumann M, Krause M Targeting the epidermal growth factor receptor in radiotherapy: radiological mechanisms, preclinical and clinical results. Radiother Oncol 2004, 72:257-266.
17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
18. Hurt CN, Nixon LS, Griffiths GO, et al. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 2011, 11:466.
19. Gwynne S, Spezi E, Wills L, et al. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. Int J Radiat Oncol Biol Phys 2012, 84:1037-1042.
20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
21. Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 2003, 39:1384-1394.
22. Wong RK, Malthaner RA, Zuraw L, Rumble BR Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys 2003, 55:930-942. for the Cancer Care Ontario Practice Guidelines Initiative Gastrointestinal Cancer Disease Site Group.
23. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14:481-489.
24. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 5500.
25. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114. on behalf of the MRC COIN Trial Investigators.
26. Lordick F, Kang Y-K, Chung H-C Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14:490-499. on behalf of the Arbeitsgemeinschaft Internistische Onkologie (AIO), EXPAND InvestigatorsEXPAND Investigators.
27. Glynne-Jones R, Mawdsley S, Harrison M Cetuximab and chemoradiation for rectal cancer-is the water getting muddy?. Acta Oncol 2010, 49:278-286.
28. Dahan L, Sadok A, Formento J-L, Seitz JF, Kovacic H Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol 2009, 158:610-620.
29. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012, 30:1755-1762.
30. Paterson AL, O'Donovan M, Provenzano E, et al. Characterisation of the timing and prevalence of receptor tyrosine kinase expression changes in esophageal carcinogenesis. J Pathol 2012, 230:118-128.
31. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
32. Button M, Staffurth J, Crosby T National variations in the treatment of oesophageal carcinoma with chemo-radiotherapy. Clin Oncol (R Coll Radiol) 2007, 19:S25.
33. Nixon L, Wills L, Staffurth J, Crosby T, Casbard A, Griffiths G Implementation of a QA RT substudy for SCOPE 1: preliminary results for test cases. Clin Oncol 2009, 21:255.
34. Peters LJ, O'Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010, 28:2996-3001.
35. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000, 18:3202.
36. Leong T, Everitt C, Yuen K, et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 2006, 78:254-261.
37. Guidance on commissioning cancer services: improving outcomes in upper gastro-intestinal cancers. NHS Executive Catalogue Number 23943 2001, NHS Executive, NHS Executive, London.
38. Groene O, Cromwell DA, Hardwick R, Riley S, Crosby T, Greenaway K The National Oesophageal-Gastric Cancer Audit: 2012 annual report 2012, The Royal College of Surgeons of England, London.
39. Leichman LP, Goldman BH, Bohanes PO, et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol 2011, 29:4555-4560.
40. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. for the ToGA Trial Investigators.
41. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006, 78:236-244.